In short: A robotic hair transplant uses the ARTAS system to assist a physician with selected steps of FUE surgery. The device does not replace the surgeon, and its labelled population is narrow. Comparative evidence is limited, so the clinic’s assessment, operator and aftercare matter more than marketing claims of an outcome advantage.
A robotic hair transplant uses an image-guided system to assist a physician with selected stages of follicular unit extraction, or FUE. ARTAS remains under physician control, and current evidence does not show that robotic FUE produces better results for everyone (FDA 510(k) summary; 2024 pilot study).
Compare the tasks the system performs, the person who controls it and the evidence behind the clinic’s claims. The NHS places assessment and method choice with the practitioner (NHS). GetHair can arrange a consultation with a partner clinic, while that clinic assesses suitability, recommends a method and performs the operation.
What is a robotic hair transplant?
In current patient marketing, robotic hair transplantation usually refers to the ARTAS system. The FDA describes ARTAS as an interactive, image-guided, computer-assisted system with a robotic arm, imaging equipment, a needle mechanism and supporting software. It is used under physician control (FDA 510(k) summary).
ARTAS is built around FUE harvesting. FUE removes follicular units through numerous small round excisions in the donor area. Those units are then placed into recipient sites in the area being treated. The process remains surgery, and FUE can leave small round scars (ISHRS).
The term robotic can sound broader than the device’s role. The FDA record says ARTAS assists with identifying and extracting follicular units, creating recipient sites and, on the modified system, implantation. It repeatedly describes those functions as assistance under physician control rather than independent clinical decisions (FDA 510(k) summary).
The current UK manufacturer page describes ARTAS iX as a CE-marked system intended to assist physicians with the same stages. Its claims about precision, efficiency and patient experience come from the manufacturer and should not be treated as independent proof of a better cosmetic outcome (Venus ARTAS iX).
Which tasks remain with the clinical team?
The FDA summary places ARTAS under physician control, while the manufacturer calls it a system that assists physicians (FDA 510(k) summary; Venus ARTAS iX).
The clinical team still has to assess the cause and pattern of hair loss, review medical history, plan donor use, agree the proposed hairline and obtain consent. The NHS advises asking about the practitioner’s qualifications and experience, why a particular procedure is recommended, common complications and follow-up arrangements (NHS).
Recipient-site design also needs human judgement. Implantation is conceptually separate from harvesting, even when a system can assist both stages. ISHRS explains that FUE and FUT describe how donor follicles are obtained, while grafts are inserted into recipient-site incisions in the target area (ISHRS).
Ask what the clinic means by robotic. Find out the exact system and version, which steps it will perform, who operates it, who makes the design decisions and what happens if the device cannot complete a planned step. For ARTAS, the answers should identify the physician controlling the system and the staff handling grafts and aftercare.
Who falls within the labelled population?
The FDA 510(k) summary states that ARTAS is indicated for scalp harvesting in men diagnosed with androgenetic alopecia who have black or brown straight hair. The current UK manufacturer page gives the same narrow population in its CE-mark indication (FDA 510(k) summary; Venus ARTAS iX).
That wording does not cover women, other hair colours or textures, body-hair harvesting or other causes of hair loss. It also does not establish suitability for every person within the labelled group (FDA 510(k) summary; Venus ARTAS iX). The partner clinic must diagnose the loss and assess the scalp, donor area, medical history and proposed design.
The FDA document records a Class II 510(k) substantial-equivalence decision. It should be described as clearance, not FDA approval, and it does not establish that ARTAS gives superior growth, safety or appearance (FDA 510(k) summary).
If a clinic proposes robotic treatment outside the population described in the device information, ask it to explain the regulatory and clinical basis in writing. The published indication itself covers only the stated population (FDA 510(k) summary; Venus ARTAS iX).
How does ARTAS compare with manual FUE?
A 2024 split-scalp pilot provides limited comparative evidence from 13 Chinese men aged 25 to 35 with androgenetic alopecia. One side of each donor area underwent ARTAS harvesting and the other manual FUE, with one surgeon carrying out the procedures at a single centre (2024 pilot study).
The ARTAS side had a total yield of 82.05% compared with 90.03% for manual FUE, but that difference was not statistically significant. Its discard rate was 10.71% compared with 5.46%, a statistically significant difference. Transection rates were 13.17% and 13.96%, with no statistically significant difference (2024 pilot study).
The study found no statistically significant difference in 12-month satisfaction and observed no complications in its small sample. Neither finding proves equivalence or population-wide safety. ARTAS was always performed first, the sample was small, and the results came from one surgeon and one centre (2024 pilot study).
The study’s small, single-centre sample does not justify claims that robotic harvesting is universally faster, more accurate, safer or more successful (2024 pilot study). Results from ARTAS also cannot be transferred automatically to another device. Ask a clinic for evidence that matches its machine, operator, proposed use and outcome claim.
Risks and what can go wrong
Robotic harvesting does not remove the ordinary risks of hair-transplant surgery. The NHS lists bleeding, infection and allergic reaction to anaesthetic. It also says a transplant may not take, a noticeable scar may form and native hair may continue to thin around the transplanted area (NHS).
ISHRS says FUE almost always leaves small round scars and warns that poor execution can cause diffuse donor thinning and visible scarring. Robotic assistance does not change the fact that follicles are removed through many small donor excisions (ISHRS).
Ask about operator training, manual fallback, maintenance, calibration and how the team responds if imaging or extraction is interrupted. The FDA record establishes the device’s functions and physician control, not a complication-free procedure (FDA 510(k) summary).
If treatment is abroad, plan follow-up before booking. The NHS page on going abroad for treatment advises comprehensive insurance. Its detailed guidance says to research the provider and facilities, arrange medical-record exchange and aftercare at home, understand the complaints route and check specialist insurance because standard policies may exclude planned treatment (NHS medical-treatment guidance).
GetHair arranges consultations, travel and aftercare contact. The partner clinic assesses, obtains consent, operates the system, performs the surgery and provides clinical aftercare. NHS guidance supports confirming the aftercare route before travelling for treatment (NHS medical-treatment guidance).
Questions to ask the clinic
- Which ARTAS model and software version will you use?
- Which stages will the device perform, and which will be manual?
- Who controls the system and who makes the hairline and donor-plan decisions?
- Does my diagnosis and hair type fall within the device’s labelled population?
- Why do you recommend robotic rather than manual FUE in my case?
- What evidence supports each claim you make about yield, scarring or recovery?
- What is the manual fallback if the system cannot complete a step?
- Who provides clinical follow-up and handles complications after I return home?
Talk it through
If you are comparing robotic and manual FUE, GetHair can arrange a free consultation with a partner clinic. The clinic can assess your hair loss, explain who performs each stage and set out why its proposed method fits the clinical plan.